Santosh Kumar
Family Medicine · Blair, NENPI 1265695241
Payments from drug & device makers
Across 177 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$528
- Amgen$333
- Novo Nordisk$308
- Lilly USA, LLC$190
- GSK$161
- Johnson & Johnson$115
- plus $913 from 24 others
What the payments were for
- Food & beverage$2,548100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $528 |
| Amgen | 25 | $333 |
| Novo Nordisk | 22 | $308 |
| Lilly USA, LLC | 8 | $190 |
| GSK | 15 | $161 |
| Johnson & Johnson | 9 | $115 |
| Bayer | 6 | $106 |
| Mylan Specialty L.p. | 3 | $100 |
| Biohaven Pharmaceuticals, Inc. | 4 | $69 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| AstraZeneca | 4 | $57 |
| Merck | 4 | $57 |
| Nestle Healthcare Nutrition Inc. | 4 | $52 |
| Novartis | 3 | $47 |
| Pfizer | 3 | $38 |
| Amarin Pharma, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Boehringer Ingelheim | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Medicure Pharma Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
How this compares
$2,548 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,197 |
| Methylprednisolone | 14 | $125 |
| Ciprofloxacin Hcl | 12 | $84 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $51 |
| Tramadol Hcl | 11 | $30 |
| Azithromycin | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $38 | $6,19711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Blair
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.